
INCY
Healthcare · Biotechnology · $24.66B market cap
$120.97-0.73 (-0.6%)Nov 13, 4:18 PM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +0.8% over 90 days · 30-day revisions 4 up, 7 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Oct 29, 2026 | Before the open | -4.27 | -3.79 | +11.2% |
| Jul 28, 2026 | Before the open | 1.76 | 2.80 | +59.1% |
| Apr 28, 2026 | Before the open | 1.34 | 1.81 | +35.1% |
| Feb 10, 2026 | Before the open | 1.92 | 1.80 | -6.3% |
| Oct 28, 2025 | Before the open | 1.64 | 2.26 | +37.8% |
| Jul 29, 2025 | Before the open | 1.47 | 1.57 | +6.8% |
| Apr 29, 2025 | Before the open | 1.03 | 1.16 | +12.6% |
| Feb 10, 2025 | Before the open | 1.55 | 1.43 | -7.7% |
| Oct 29, 2024 | Before the open | 1.09 | 1.07 | -1.8% |
| Jul 30, 2024 | Before the open | 1.11 | -1.82 | -264.0% |
| Apr 30, 2024 | Before the open | 0.83 | 0.64 | -22.9% |
| Feb 13, 2024 | Before the open | 1.15 | 1.06 | -7.8% |
| Oct 31, 2023 | Before the open | 1.07 | 1.10 |
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive…
| +2.8% |
| Aug 1, 2023 | Before the open | 0.87 | 0.99 | +13.8% |
| May 2, 2023 | Before the open | 0.74 | 0.37 | -50.0% |
| Feb 7, 2023 | Before the open | 0.57 | 0.62 | +8.8% |
| Nov 1, 2022 | Before the open | 0.71 | 0.60 | -15.5% |
| Aug 2, 2022 | Before the open | 0.75 | 1.01 | +34.7% |
| May 3, 2022 | Before the open | 0.69 | 0.55 | -20.3% |
| Feb 8, 2022 | Before the open | 0.87 | 0.10 | -88.5% |
| Nov 2, 2021 | Before the open | 0.76 | 1.18 | +55.3% |
| Aug 3, 2021 | Before the open | 0.74 | 0.80 | +8.1% |
| May 4, 2021 | Before the open | 0.64 | 0.67 | +4.7% |
| Feb 9, 2021 | Before the open | 0.77 | 0.93 | +20.8% |
| Nov 5, 2020 | Before the open | 0.76 | 0.23 | -69.7% |
| Aug 4, 2020 | Before the open | 0.86 | 1.24 | +44.2% |
| May 5, 2020 | Before the open | -2.80 | -2.86 | -2.1% |
| Feb 13, 2020 | Before the open | 0.58 | 0.65 | +12.1% |
| Oct 29, 2019 | Before the open | 0.64 | 0.82 | +28.1% |
| Jul 30, 2019 | Before the open | 0.50 | 0.75 | +50.0% |
| Apr 30, 2019 | Before the open | 0.41 | 0.62 | +51.2% |
| Feb 14, 2019 | Before the open | 0.46 | 0.40 | -13.0% |
| Oct 30, 2018 | Before the open | 0.41 | 0.38 | -7.3% |
| Jul 31, 2018 | Before the open | 0.22 | 0.26 | +18.2% |
| May 1, 2018 | Before the open | 0.12 | -0.01 | -108.3% |
| Feb 15, 2018 | Before the open | -0.45 | -0.71 | -57.8% |